Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone plus Capecitabine in Adjuvant TNBC
NCT07021261Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2025
- Primary completion
- Jun 2030
- Modality
- Allosteric Modulators
01
Overview
A Phase 3 trial of utidelone in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07021261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021261.